216 related articles for article (PubMed ID: 27625244)
1. Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma - A study of 28 cases.
Kumari K; Sharma MC; Kakkar A; Malgulwar PB; Pathak P; Suri V; Sarkar C; Chandra SP; Faruq M; Gupta RK; Saran RK
Neurol India; 2016; 64(5):988-94. PubMed ID: 27625244
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
3. mTOR pathway activation in focal cortical dysplasia.
Kumari K; Sharma MC; Kakkar A; Malgulwar PB; Pathak P; Suri V; Sarkar C; Chandra SP; Faruq M
Ann Diagn Pathol; 2020 Jun; 46():151523. PubMed ID: 32325422
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
[TBL] [Abstract][Full Text] [Related]
5. Evidence of ambiguous differentiation and mTOR pathway dysregulation in subependymal giant cell astrocytoma.
Barrows BD; Rutkowski MJ; Gültekın SH; Parsa AT; Tıhan T
Turk Patoloji Derg; 2012; 28(2):95-103. PubMed ID: 22627626
[TBL] [Abstract][Full Text] [Related]
6. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
[TBL] [Abstract][Full Text] [Related]
7. Tuberin and hamartin expression is reduced in the majority of subependymal giant cell astrocytomas in tuberous sclerosis complex consistent with a two-hit model of pathogenesis.
Jóźwiak S; Kwiatkowski D; Kotulska K; Larysz-Brysz M; Lewin-Kowalik J; Grajkowska W; Roszkowski M
J Child Neurol; 2004 Feb; 19(2):102-6. PubMed ID: 15072102
[TBL] [Abstract][Full Text] [Related]
8. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.
Robb VA; Astrinidis A; Henske EP
Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396
[TBL] [Abstract][Full Text] [Related]
9. Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.
Fuchs A; König K; Heukamp LC; Fassunke J; Kirfel J; Huss S; Becker AJ; Büttner R; Majores M
Diagn Pathol; 2014 Mar; 9():48. PubMed ID: 24593867
[TBL] [Abstract][Full Text] [Related]
10. mTOR cascade activation distinguishes tubers from focal cortical dysplasia.
Baybis M; Yu J; Lee A; Golden JA; Weiner H; McKhann G; Aronica E; Crino PB
Ann Neurol; 2004 Oct; 56(4):478-87. PubMed ID: 15455405
[TBL] [Abstract][Full Text] [Related]
11. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
12. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
13. Tuberin, p27 and mTOR in different cells.
Burgstaller S; Rosner M; Lindengrün C; Hanneder M; Siegel N; Valli A; Fuchs C; Hengstschläger M
Amino Acids; 2009 Feb; 36(2):297-302. PubMed ID: 18386114
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin.
Tee AR; Anjum R; Blenis J
J Biol Chem; 2003 Sep; 278(39):37288-96. PubMed ID: 12867426
[TBL] [Abstract][Full Text] [Related]
15. Tumour suppressors hamartin and tuberin: intracellular signalling.
Krymskaya VP
Cell Signal; 2003 Aug; 15(8):729-39. PubMed ID: 12781866
[TBL] [Abstract][Full Text] [Related]
16. Analysis of TSC1 mutation spectrum in mucosal melanoma.
Ma M; Dai J; Xu T; Yu S; Yu H; Tang H; Yan J; Wu X; Yu J; Chi Z; Si L; Cui C; Sheng X; Kong Y; Guo J
J Cancer Res Clin Oncol; 2018 Feb; 144(2):257-267. PubMed ID: 29185092
[TBL] [Abstract][Full Text] [Related]
17. Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.
Tyburczy ME; Kotulska K; Pokarowski P; Mieczkowski J; Kucharska J; Grajkowska W; Roszkowski M; Jozwiak S; Kaminska B
Am J Pathol; 2010 Apr; 176(4):1878-90. PubMed ID: 20133820
[TBL] [Abstract][Full Text] [Related]
18. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas.
Plank TL; Logginidou H; Klein-Szanto A; Henske EP
Mod Pathol; 1999 May; 12(5):539-45. PubMed ID: 10349994
[TBL] [Abstract][Full Text] [Related]
19. Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase.
Buccoliero AM; Caporalini C; Giordano F; Mussa F; Scagnet M; Moscardi S; Baroni G; Genitori L; Taddei GL
Clin Neuropathol; 2016; 35(5):295-301. PubMed ID: 27390104
[TBL] [Abstract][Full Text] [Related]
20. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
Cheng S; Hawkins C; Taylor MD; Bartels U
Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
